Recent news coverage relevant to Entera Bio primarily relates to geopolitical and economic conditions affecting Israel and the broader region, with no direct business developments reported.

• Entera Bio operates in a region affected by ongoing geopolitical tensions and conflicts involving Israel and neighboring entities, which have been widely reported in recent news [N1][N2][N3][N4][N5][N6][N7][N8].
• No direct recent business news or operational updates specific to Entera Bio were identified in the recent news business feed [N1][N2][N3][N4][N5][N6][N7][N8].

The company maintains a strong liquidity position with substantial cash reserves, supporting ongoing research and development activities despite the absence of revenue. Its access to Israeli Innovation Authority grants provides financial support and potential protection of intellectual property through regulatory restrictions on technology transfer. The company's diversified operational footprint, with clinical and supply chain activities outside Israel, may mitigate some geopolitical risks. Continued management of geopolitical and currency risks could support stable operations and progress in product development.

Entera Bio faces significant geopolitical risks due to ongoing conflicts and instability in the Middle East, which could escalate and materially disrupt operations or damage facilities. Regulatory restrictions from the Israeli Innovation Authority may limit the company's ability to transfer technology or engage in certain transactions, potentially hindering business flexibility. Currency exchange fluctuations between the U.S. dollar and Israeli Shekel may adversely affect earnings and operational costs. The company currently reports no revenue and a net loss, indicating ongoing reliance on financing and grants, which may be challenged by geopolitical and economic conditions. Legal and governance complexities under Israeli law may also complicate shareholder rights and corporate transactions.

Entera Bio's moat is influenced by its receipt of grants from the Israeli Innovation Authority, which provides funding but also imposes regulatory restrictions on technology transfer and intellectual property rights. This creates barriers to transferring technology outside Israel without approval, potentially limiting competition and protecting proprietary know-how. The company's operations in Israel, despite geopolitical risks, benefit from local expertise and infrastructure. However, the moat is tempered by geopolitical instability and regulatory constraints that may affect operational flexibility and capital raising.

• Geopolitical and Security Risks: Ongoing conflicts involving Israel, Hamas, Hezbollah, Iran, and other regional actors create uncertainty and potential for operational disruptions, damage to facilities, and workforce impacts due to military service obligations.
• Regulatory Restrictions from Israeli Innovation Authority: Restrictions on transferring IIA-financed technologies and intellectual property require approvals and may impose financial penalties, limiting business flexibility and potential transactions.
• Currency Exchange Risk: Fluctuations between the U.S. dollar and Israeli Shekel affect operational costs and earnings, with no current hedging arrangements in place.
• Legal and Governance Risks: Incorporation under Israeli law affects shareholder rights, corporate governance, and may delay or complicate change of control transactions, potentially depressing share price.
• Financial Performance and Liquidity: The company reports no revenue and a net loss, relying on cash reserves and grants to fund operations, which may be impacted by geopolitical and economic conditions affecting capital raising.

• Entera Bio Ltd. is an Israeli company with principal research facilities and key personnel located in Israel.
• The company receives grants from the Israeli Innovation Authority (IIA) and is subject to restrictions on transferring IIA-financed technologies and related intellectual property rights, requiring IIA approval for transfers, especially outside Israel, with potential financial penalties for unauthorized transfers.
• The company operates in a geopolitical environment marked by ongoing conflicts and instability in the Middle East, including hostilities involving Israel, Hamas, Hezbollah, Iran, and other regional actors.
• Despite the regional conflicts and military activities, Entera Bio's business and operations have not been materially impacted to date, and no delays to programs have been reported due to these conflicts.
• The company’s research and some management are located in Israel, while clinical, regulatory, and supply chain activities are conducted outside Israel.
• Entera Bio is exposed to currency exchange risk, particularly fluctuations between the U.S. dollar and the Israeli Shekel (NIS), which affects its expenses and earnings.
• The company is incorporated under Israeli law, which affects shareholder rights and corporate governance, including provisions that may delay or complicate change of control transactions.
• As of September 30, 2026, Entera Bio had cash and cash equivalents of approximately $265.9 million USD and current assets of approximately $276.5 million USD, with current liabilities of about $2.15 million USD, resulting in a very strong current ratio of 128.41 and a cash ratio of 123.49.
• The company reported zero revenue and a net loss of approximately $15.6 million USD for the quarter ending September 30, 2026.
• Basic and diluted earnings per share were reported as $0.11 for the same period.
• Recent news coverage relevant to the company or its sector includes geopolitical developments and economic conditions affecting Israel and the broader region, but no direct business news about Entera Bio was identified in the recent news business feed.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.